Supplementary Tables S1-S4 from miR-1202 acts as anti-oncomiR in myeloid leukaemia by down-modulating GATA-1_S expression

Abstract

Table S1. Clinical and molecular characterization of TMD/AML-DS patients with GATA-1 mutations. Table S2. Mutant sequences within or outside the putative hsa-miR-1202 binding site generated in the psiCHECK™-2 Vector GATA1 exon2 construct. Table S3. Primer sequences used for quantitative Real-time PCR analysis.Table S4. Antibodies used for western blot analysis